PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884075
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884075
Neurology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of neurology drugs Market
The global neurology drugs market continues to expand as neurological disorders become more prevalent worldwide and scientific advancements reshape therapeutic approaches. According to the latest findings, the market was valued at USD 82.47 billion in 2024, supported by rising healthcare spending, new drug launches, and technological innovations in neurological diagnostics. The market is projected to increase to USD 87.26 billion in 2025 as treatment adoption rises, and reach USD 134.15 billion by 2032, driven by rapid advancements in biologics, gene therapies, and personalized medicine.
Neurology drugs are essential for managing conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and cerebrovascular disorders, all of which are becoming more widespread due to aging populations and improved diagnosis capabilities. Increasing investments in genetic research, digital neurology tools, and biomarker development are enabling targeted therapeutic solutions. Prominent pharmaceutical companies-Novartis AG, Bayer AG, Pfizer Inc., and Sanofi-maintain strong positions due to extensive product portfolios, strategic acquisitions, and global market presence.
Market Dynamics
Drivers
A major driver of market growth is the increasing prevalence of neurological disorders. According to the WHO (2024), more than 1 in 3 individuals worldwide are affected by neurological conditions, indicating a substantial rise in the global disease burden. Growing awareness campaigns and improved access to diagnostics have enhanced early detection, driving higher demand for neurology medications. As populations in developed and emerging countries continue to age, the need for long-term neurological care is expected to rise significantly.
Restraints
The high cost of treatment remains a significant barrier to market expansion. Neurology drugs require extensive R&D, multi-phase clinical trials, and rigorous regulatory approvals, which increase development costs. This ultimately raises drug prices, placing financial pressure on both patients and healthcare systems. For instance, the American Academy of Neurology reported that multiple sclerosis treatment costs reached USD 2,378 annually in 2021, with expenses rising each year. Such increasing treatment burdens continue to limit affordability in low-income and middle-income regions.
Trends
The market is experiencing a transformative shift due to technological advancements. Tools such as AI-assisted diagnosis, brain-computer interfaces (BCIs), wearables, virtual reality (VR) rehabilitation systems, and advanced neuroimaging technologies are enhancing disease management. Gene therapies are emerging as powerful approaches for genetic disorders, while biologics and monoclonal antibodies are gaining momentum due to their targeted mechanism of action and reduced adverse effects. Investments in therapies for rare neurological diseases are increasing, supported by government incentives and exclusive marketing rights.
Opportunities
Growing adoption of personalized medicine presents significant opportunities. Tailored treatments based on patient genetics, biomarkers, and specific disease mechanisms are expected to improve outcomes and minimize side effects. This shift is driving pharmaceutical companies to invest in advanced drug design and precision-based therapies.
Challenges
The complexity of neurological disorders poses major scientific challenges. Neurological diseases are often multifactorial, with varied patient responses and difficult-to-access brain targets. Difficulties in drug delivery across the blood-brain barrier, limited healthcare infrastructure in developing regions, and challenges in patient recruitment for rare diseases impede drug development timelines.
Segmentation Insights
By Indication
Alzheimer's disease is projected to dominate the market due to rising prevalence and increasing awareness campaigns that support early diagnosis and treatment. The U.S. currently has approximately 7.2 million people living with Alzheimer's.
Multiple sclerosis is expected to grow steadily as companies intensify R&D for novel therapies.
By Drug Class
Cholinesterase inhibitors hold the largest share due to high usage and recent product approvals. The 2021 FDA approval of ADUHELM for Alzheimer's disease has strengthened the segment.
NMDA receptor antagonists are also expanding due to new launches and technology-driven improvements.
By Route of Administration
The oral segment dominated in 2024 due to high patient compliance and ease of long-term use.
The parenteral segment is expected to grow as more biologics and targeted therapies enter the market.
By Distribution Channel
Hospital pharmacies accounted for the largest share in 2024 due to higher prescription rates and greater patient inflow.
Retail and online pharmacies are projected to grow with increased accessibility and consumer convenience.
Regional Outlook
North America dominated the neurology drugs market in 2024, holding 50.96% market share, valued at USD 42.03 billion. The U.S. leads in innovation, early adoption of advanced therapies, and strong patient diagnosis rates. Europe is the second-largest market, supported by robust healthcare infrastructure and high awareness levels. The Asia Pacific region is expected to grow at the fastest pace, fueled by rising disease prevalence, healthcare investments, and growing elderly populations in China and India. Latin America and the Middle East & Africa show steady growth supported by improved reimbursement and public health initiatives.
Segmentation By Indication
- Alzheimer's Disease
- Multiple Sclerosis
- Epilepsy
- Parkinson's Disease
- Others
By Drug Class
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- Antiepileptic Drugs
- Immunomodulatory Drugs
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
By Region
- North America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- U.S.
- Canada
- Europe (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Neurological Disorders, By Key Countries/Regions
- 4.2. Regolatory Framework, By Key Countries/Regions
- 4.3. Reimbursement Scenario, By Key Countries/Regions
- 4.4. New Product Launches & Approvals, By Key Players
- 4.5. Key Industry Developments (Merger, Acquisition, Collaboration, etc.)
5. Global Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Indication
- 5.1.1. Alzheimer's Disease
- 5.1.2. Moltiple Sclerosis
- 5.1.3. Epilepsy
- 5.1.4. Parkinson's Disease
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Drug Class
- 5.2.1. Cholinesterase Inhibitors
- 5.2.2. NMDA Receptor Antagonist
- 5.2.3. Antiepileptic Drugs
- 5.2.4. Immunomodolatory Drugs
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies & Drug Stores
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Indication
- 6.1.1. Alzheimer's Disease
- 6.1.2. Moltiple Sclerosis
- 6.1.3. Epilepsy
- 6.1.4. Parkinson's Disease
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Drug Class
- 6.2.1. Cholinesterase Inhibitors
- 6.2.2. NMDA Receptor Antagonist
- 6.2.3. Antiepileptic Drugs
- 6.2.4. Immunomodolatory Drugs
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies & Drug Stores
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Indication
- 7.1.1. Alzheimer's Disease
- 7.1.2. Moltiple Sclerosis
- 7.1.3. Epilepsy
- 7.1.4. Parkinson's Disease
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Drug Class
- 7.2.1. Cholinesterase Inhibitors
- 7.2.2. NMDA Receptor Antagonist
- 7.2.3. Antiepileptic Drugs
- 7.2.4. Immunomodolatory Drugs
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies & Drug Stores
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Indication
- 8.1.1. Alzheimer's Disease
- 8.1.2. Moltiple Sclerosis
- 8.1.3. Epilepsy
- 8.1.4. Parkinson's Disease
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Drug Class
- 8.2.1. Cholinesterase Inhibitors
- 8.2.2. NMDA Receptor Antagonist
- 8.2.3. Antiepileptic Drugs
- 8.2.4. Immunomodolatory Drugs
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies & Drug Stores
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Indication
- 9.1.1. Alzheimer's Disease
- 9.1.2. Moltiple Sclerosis
- 9.1.3. Epilepsy
- 9.1.4. Parkinson's Disease
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Drug Class
- 9.2.1. Cholinesterase Inhibitors
- 9.2.2. NMDA Receptor Antagonist
- 9.2.3. Antiepileptic Drugs
- 9.2.4. Immunomodolatory Drugs
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies & Drug Stores
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Indication
- 10.1.1. Alzheimer's Disease
- 10.1.2. Moltiple Sclerosis
- 10.1.3. Epilepsy
- 10.1.4. Parkinson's Disease
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Drug Class
- 10.2.1. Cholinesterase Inhibitors
- 10.2.2. NMDA Receptor Antagonist
- 10.2.3. Antiepileptic Drugs
- 10.2.4. Immunomodolatory Drugs
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies & Drug Stores
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 10.5.1. South Africa
- 10.5.2. GCC
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Eisai Co., Ltd.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. Financials (Based on Availability)
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. SWOT, etc.
- 11.2.2. Strategies
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. Financials (Based on Availability)
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. SWOT, etc.
- 11.2.3. Biogen Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. Financials (Based on Availability)
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. SWOT, etc.
- 11.2.4. Bayer AG
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. Financials (Based on Availability)
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. SWOT, etc.
- 11.2.5. Pfizer Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. Financials (Based on Availability)
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. SWOT, etc.
- 11.2.6. Johnson & Johnson Services, Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. Financials (Based on Availability)
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. SWOT, etc.
- 11.2.7. Novartis AG
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. Financials (Based on Availability)
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. SWOT, etc.
- 11.2.8. Merck KGaA
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. Financials (Based on Availability)
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. SWOT, etc.
- 11.2.9. Sanofi
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. Financials (Based on Availability)
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. SWOT, etc.
- 11.2.10. AbbVie Inc.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. Financials (Based on Availability)
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. SWOT, etc.
- 11.2.1. Eisai Co., Ltd.
List of Tables
- Table 1: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
- Table 2: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
- Table 3: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 4: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 5: Global Neurology Drugs Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 6: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
- Table 7: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
- Table 8: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 9: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 10: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 11: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
- Table 12: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
- Table 13: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 14: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 15: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
- Table 16: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
- Table 17: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
- Table 18: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 19: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 20: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
- Table 21: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
- Table 22: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
- Table 23: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 24: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 25: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
- Table 26: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
- Table 27: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
- Table 28: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
- Table 29: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
- Table 30: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
List of Figures
- Figure 1: Global Neurology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Neurology Drugs Market Value Share (%), By Indication, 2024 & 2032
- Figure 3: Global Neurology Drugs Market Value Share (%), By Drug Class, 2024 & 2032
- Figure 4: Global Neurology Drugs Market Value Share (%), By Route of Administration, 2024 & 2032
- Figure 5: Global Neurology Drugs Market Value Share (%), By Distribution Channel, 2024 & 2032
- Figure 6: Global Neurology Drugs Market Value (USD billion), by Region, 2024 & 2032
- Figure 7: North America Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
- Figure 8: North America Neurology Drugs Market Value Share (%), By Indication, 2024
- Figure 9: North America Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
- Figure 10: North America Neurology Drugs Market Value Share (%), By Drug Class, 2024
- Figure 11: North America Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 12: North America Neurology Drugs Market Value Share (%), By Route of Administration, 2024
- Figure 13: North America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 14: North America Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
- Figure 15: North America Neurology Drugs Market Value (USD billion), By Country, 2024 & 2032
- Figure 16: North America Neurology Drugs Market Value Share (%), By Country, 2024
- Figure 17: Europe Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
- Figure 18: Europe Neurology Drugs Market Value Share (%), By Indication, 2024
- Figure 19: Europe Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
- Figure 20: Europe Neurology Drugs Market Value Share (%), By Drug Class, 2024
- Figure 21: Europe Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 22: Europe Neurology Drugs Market Value Share (%), By Route of Administration, 2024
- Figure 23: Europe Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 24: Europe Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
- Figure 25: Europe Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 26: Europe Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
- Figure 27: Asia Pacific Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
- Figure 28: Asia Pacific Neurology Drugs Market Value Share (%), By Indication, 2024
- Figure 29: Asia Pacific Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
- Figure 30: Asia Pacific Neurology Drugs Market Value Share (%), By Drug Class, 2024
- Figure 31: Asia Pacific Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 32: Asia Pacific Neurology Drugs Market Value Share (%), By Route of Administration, 2024
- Figure 33: Asia Pacific Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
- Figure 35: Asia Pacific Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 36: Asia Pacific Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
- Figure 37: Latin America Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
- Figure 38: Latin America Neurology Drugs Market Value Share (%), By Indication, 2024
- Figure 39: Latin America Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
- Figure 40: Latin America Neurology Drugs Market Value Share (%), By Drug Class, 2024
- Figure 41: Latin America Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 42: Latin America Neurology Drugs Market Value Share (%), By Route of Administration, 2024
- Figure 43: Latin America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 44: Latin America Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
- Figure 45: Latin America Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 46: Latin America Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
- Figure 47: Middle East & Africa Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
- Figure 48: Middle East & Africa Neurology Drugs Market Value Share (%), By Indication, 2024
- Figure 49: Middle East & Africa Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
- Figure 50: Middle East & Africa Neurology Drugs Market Value Share (%), By Drug Class, 2024
- Figure 51: Middle East & Africa Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
- Figure 52: Middle East & Africa Neurology Drugs Market Value Share (%), By Route of Administration, 2024
- Figure 53: Middle East & Africa Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
- Figure 55: Middle East & Africa Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 56: Middle East & Africa Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
- Figure 57: Global Neurology Drugs Market Share (%), By Company, 2024
